Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07217873

IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study

IntraVenous Iron in Kids With Iron Deficiency and Scoliosis

Status
Recruiting
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
120 (estimated)
Sponsor
Columbia University · Academic / Other
Sex
All
Age
10 Years – 19 Years
Healthy volunteers
Not accepted

Summary

Adolescents and young adults undergoing spinal fusion surgery for the correction of scoliosis and other spinal deformity are at high risk of perioperative iron deficiency and anemia, yet the means and evidence for optimizing iron status have not been described in this setting. The proposed study is a randomized controlled trial of preoperative intravenous iron supplementation, to identify whether iron deficiency is a modifiable risk factor for adverse surgical outcomes such as red blood cell transfusion and diminished postoperative cognitive and physical capacity in this vulnerable population. Building evidence for patient blood management interventions such as iron supplementation is vital to ensuring high quality care of surgical patients and may reduce unnecessary transfusions amid recent blood shortages.

Detailed description

Adolescents undergoing spinal fusion surgery for scoliosis and/or kyphosis are poised to benefit from preoperative iron supplementation. Spinal fusion carries a risk of large surgical blood losses and perioperative red blood cell transfusion, which are associated with adverse outcomes in this population. These patients are mostly adolescent females, a group more susceptible to iron deficiency and resulting anemia at baseline due to iron losses with menses, and who suffer an additional insult to iron stores during surgery. Nevertheless, iron status is not routinely monitored in this setting and there is no standard of care for preoperative iron supplementation. Iron is a nutritionally essential trace element important not only for red blood cell production, but also for muscle function and neurotransmitter synthesis and signaling. Therefore, supplementation of poor iron status is an important target for optimizing hemoglobin prior to surgery, reducing transfusion rates and associated complications such as alloimmunization, and improving patient outcomes. On its own and as the primary cause of anemia, iron deficiency was identified as the only risk factor for transfusion which is modifiable preoperatively. In addition, iron supplementation is shown to alleviate impairments of physical and cognitive capacity associated with even mild forms of iron deficiency in adolescent and young adult females. A pilot study conducted at Columbia University Irving Medical Center identified iron deficiency in 36% of scoliosis patients prior to surgery, with preoperative iron status highly correlated with iron status during surgical recovery. Consequently, the investigators plan to examine iron deficiency as a modifiable risk factor for transfusion and impaired postoperative cognitive and physical capacity in this vulnerable population. Previous trials of brief iron interventions in high-risk adult surgical patients, mostly with unknown iron status, do not inform the care of adolescents and were not designed to address postoperative functional outcomes. The investigators will therefore perform a single-center randomized controlled trial in which adolescents with scoliosis and/or kyphosis identified using physiologically-based serum markers of poor iron status will be randomized to a one time preoperative dose of IV ferric carboxymaltose or placebo, to test the hypotheses that preoperative iron supplementation 1) reduces the rate of red blood cell transfusion, 2) improves postoperative neurocognition compared to a preoperative baseline, and 3) improves patient reported physical functioning during recovery. This study aims to improve outcomes in this vulnerable population and provide evidence for patient blood management approaches to reduce transfusions amid recent severe blood shortages.

Conditions

Interventions

TypeNameDescription
DRUGFerric carboxymaltose IVFerric carboxymaltose is an intravenous treatment for iron deficiency.
DRUGNormal Saline (Placebo)Normal saline is the recommended diluent for ferric carboxymaltose, and on its own serves as the placebo control for this study.

Timeline

Start date
2025-11-21
Primary completion
2027-08-31
Completion
2027-10-31
First posted
2025-10-20
Last updated
2025-11-26

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT07217873. Inclusion in this directory is not an endorsement.